ATyr Pharma, Inc.
 | |
| | |
| aTyr Pharma, Inc. | |
|---|---|
| Type | Public |
| Industry | Biotechnology |
| Founded | 2005 |
| Headquarters | San Diego, CA, United States |
| Key people | John D. Mendlein (CEO), Kelly Blackburn, Melissa Ashlock, Catharine Johnson, Ying J. Buechler |
| Investors | Alta Partners, Cardinal Partners, Domain Associates, Polaris Partners, Silicon Valley Bank, Sofinnova Ventures, Solar capital [1] |
| Number of employees | 49 [2] |
aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. It is a biotherapeutics company, engages in the discovery and clinical development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases.The company develops Resolaris, which is in Phase Ib/II clinical trials for treating adult patients with facioscapulohumeral muscular dystrophy (FSHD), a rare genetic myopathy with an immune component. [3]
aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures. [4]
Contents
Products
- The Company's lead candidate, Resolaris™, is a potential first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component.
- Resolaris is currently in a Phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (FSHD); a Phase 1b/2 trial in adult patients with limb-girdle muscular dystrophy 2B (LGMD2B or dysferlinopathies) or FSHD; and a Phase 1b/2 trial in patients with an early onset form of FSHD.
- To protect this pipeline, aTyr has built an intellectual property estate comprising over 80 issued or allowed patents and over 230 pending patent applications that are owned or exclusively licensed by aTyr, including over 300 potential Physiocrine-based protein compositions.
- aTyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation for which there are currently limited or no treatment options.
Controversies
Top 5 Recent Tweets
| Date | Author | Comment |
|---|---|---|
| April 11, 2023 | AthenaSTEMWomen | Activating & Scaling More Men as Allies | Role-Playing Workshop | Powered by @aTyrNews Apr 27, 4:30 PM – 6:30 PM P… https://t.co/EzdtwK0GR4 |
| April 13, 2023 | stockresearchhq | aTyr Pharma, Inc $LIFE quarterly revenue growth rate YoY of 1325.70% ranked
⭐⭐⭐⭐⭐ in our db. Impressive! https://t.co/PpN15UvCW7 |
| April 11, 2023 | AthenaSTEMWomen | Expect this interactive workshop to engage leaders by identifying & calling out common gender bias situations. Join… https://t.co/7EzWbSB0hF |
| April 11, 2023 | AthenaSTEMWomen | Research suggests that men who participate in allyship programming are 2-3x more likely to recognize common gender… https://t.co/OfpA7DnQ4W |
Top 5 Recent News Headlines
Top 5 Lifetime Tweets
Top 5 Lifetime News Headlines
- ↑ https://www.crunchbase.com/organization/atyr-pharma#/entity
- ↑ http://www.nasdaq.com/markets/ipos/company/atyr-pharma-inc-686434-78065
- ↑ http://www.prnewswire.com/news-releases/atyr-pharma-announces-second-quarter-2016-operating-results-300311952.html
- ↑ https://www.crunchbase.com/organization/atyr-pharma#/entity
- ↑ https://www.linkedin.com/company/atyr-pharma
Top Authors
Verification history
2,940 days ago- View all verifications
